



Cardiac and Vascular Complications of COVID-19: A Review

Aaron Schmid¹, Marija Petrovic¹, Kavya Akella¹, Anisha Pareddy¹, Sumathilatha Sakthi Velavan¹

¹Division of Biomedical Sciences, Marian University College of Osteopathic Medicine
Indianapolis, IN

Pathogenesis of COVID-19 Cardiovascular Disease and Effects

Six proposed mechanisms:

1. Angiotensin converting enzyme (ACE-2) receptor-dependent myocardial infection causing direct cardiac damage. (1)
2. Hypoxia-induced injury due to oxidative stress, acidosis, and mitochondrial damage. (1)
3. Inflammation resulting in vessel hyperpermeability and angiospasm, causing damage to the heart's microvasculature. (1)
4. Systemic inflammatory reaction and cytosine storm mediating damage (1)
5. Vessel occlusion due to coagulopathy, thrombosis, embolus, plaque instability, or plaque rupture from system inflammatory response. (1)
6. Stress-induced cardiomyopathy and cardiac injury due to increases in catecholamines from a stress response in a patient. (1)



2

Vascular Complications

VTE

~31% of patients with COVID-19 in the ICU had thrombotic complications despite thromboprophylaxis.

These patients exhibited prolonged PT (prothrombin time) and aPTT (activated partial thromboplastin time) time (3).

Stroke

It is very important to screen high risk COVID-19 patients that present with comorbidities especially **hypertension** for the potential of stroke. (6)

Studies have shown that important markers in high risk patients that may indicate stroke include:
Elevated D-dimer, cardiac troponin T, prothrombin time, and c-reactive protein (7).

Concomitant venous and arterial thrombotic events

Several studies showed the presence of venous and arterial thrombosis in a high percentage of COVID-19 patients, with suggestive lab values including elevated D- dimer and elevated c-reactive protein (4,5)

Coagulopathy

Some COVID-19 patients present with a term known as COVID-19 associated coagulopathy (CAC), similar to DIC (disseminated intravascular coagulation).

CAC differs from DIC in that it has:
elevated fibrinogen levels, elevated c-reactive protein, activated complement, and presence of antiphospholipid antibodies (2,4,7-9)

Cardiac Complications

Myocarditis

Similar to COVID-19, myocarditis is often preceded by flu-like and gastrointestinal symptoms (10)
46% of patients infected with COVID-19 with no known underlying cardiac disease had abnormal echocardiography findings (11))

Cardiac Biomarkers

Elevated troponin levels in COVID-19 patients were associated with elevated levels of CRP and NT-proBNP, linking myocardial injury to severity of inflammation,, and were also associated with a more severe disease course and worse prognosis (12-15)

Heart Failure

Heart failure related to ventricular dysfunction, myocarditis, acute coronary syndrome, arrythmia, pulmonary hypertension, ARDS, and cardiomyopathy occurs in up to 23% of COVID-19 patients (16,17).

Arrhythmias




16.7% of COVID-19 patients were seen with arrhythmias with 44.4% prevalence in those who were admitted to the ICU (18, 19)

Arrhythmias could be due to myocarditis, myocardial ischemia, infection-induced hypoxia, fever, metabolic disarray, hormonal dysregulation, medication (ex. azithromycin and hydroxychloroquine COVID-19 treatments), or inflammation. (20, 21, 22, 23)

Acute Coronary Syndrome

Increased thrombotic event risk can cause increased ACS risk in COVID-19 positive patients. (24)

Myocardial injury with ST-segment elevation has been observed in positive patients in addition to reduced left ventricular ejection fraction and Brugada pattern have also been observed (25, 26-29)



The COVID-19 Patient

- Patients with later confirmed COVID-19 may initially present to the doctor because of cardiovascular symptoms such as heart palpitations and chest tightness (30,31)
- Patients may also present with elevated cardiac biomarkers, myopericarditis, angina, chest pressure, ST-elevation, and systolic dysfunction without any signs or symptoms of infection such as fever, cough, dyspnea, or respiratory involvement (32-34)
- Atrial fibrillation, ventricular dysfunction, and myocarditis are sequelae seen in COVID-19 patients despite no evidence of prior CVD, CAD, HF, cancer, hypertension, or smoking

Does the risk of cardiovascular disease persist after COVID-19 infection?

- 10-year follow-up study showed an increased risk of cardiovascular disease and cardiac complications in pneumonia patients
- COVID-19 is primarily a respiratory illness and is likely to cause similar, long-term outcomes (35)
- COVID-19-recovered patients, 2-3 months after diagnosis, showed cardiac MRI abnormalities in 78% and myocardial inflammation in 60% (36)

Conclusion

Acute cardiac injury is a common cardiovascular complication of Covid19 and little is currently known about the long term implications of the complications and manifestations. Vascular complications show a hypercoagulable state which indicates potential for thromboembolism. By monitoring for both cardiac and vascular complications after hospitalization and administering anti-platelet and anti-coagulation therapies we have seen prevention of complications such as VTE. Developing a CV screening protocol for Covid-19 patients and recovered patients is crucial in monitoring and further research.

Literature Cited

1.Kim IC, Kim HA, Park JS, Nam CW. Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives. Korean Circ J. 2020;50(7):543-54. 2."COVID-19 Chest X-Ray Guideline." COVID-19 Chest X-Ray Guideline - UCLA Radiology, Los Angeles, Westwood, Manhattan Beach, Santa Monica, CA. www.urhsageath.org/radiology/covid-19-chest-x-ray-guideline. 3.Klok, F. A., Kruip, M., van der Meer, N. J. M., Arbous, M. S., Gommers, D., Kant, K. M., ... Endeman, H. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*, 191, 145-147. doi:10.1016/j.thromres.2020.04.013. 4.Zhou, B., She, J., Wang, Y., & Ma, X. (2020). Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report. *J Thromb Thrombolysis*, 50(1), 229-232. doi:10.1007/s11239-020-02084-w. 5.Droeshch, E., Huang, M., DeSancho, M., Lee, E., Magro, C., & Harp, J. (2020). Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19. *JAMA Dermatology*. doi:10.1001/jamadermatol.2020.2800. 6.Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., ... Hu, B. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol*. doi:10.1001/jamaneurol.2020.1127. 7.Ajula, A., Nallekalle, K., Narula, N., Sapozhnikov, S., Dandu, V., Toom, S., ... Elsayeh, D. (2020). COVID-19 presenting as stroke. *Brain Behav Immun*, 87, 115-119. doi:10.1016/j.bbi.2020.04.077. 8.Iba, T., Levy, J. H., Connors, J. M., Warkentin, T. E., Thachil, J., & Levi, M. (2020). The unique characteristics of COVID-19 coagulopathy. *Crit Care*, 24(1), 360. doi:10.1186/s13054-020-03077-0. 9.Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., ... Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*, 395(10223), 507-513. doi:10.1016/S0140-6736(20)30181-7. 10.Calvano AL, Marcelongro R, Basco C, Ilieco S. Clinical presentation and diagnosis of myocarditis. *Heart*. 2015;101(11):1332-41. 11.Dweck MR, Bulugir A, Hahn RT, Bing R, Lee RK, Chapman AB, et al. Global evaluation of echocardiography in patients with COVID-19. *Eur Heart J Cardiovasc Imaging*. 2020. 12.Ortgin E, Madhavan MV, Bickel B, Chuich T, Laracy J, Biondi-Zoccali G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. *J Am Coll Cardiol*. 2020;75(18):2352-71. 13.Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fetal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020. 14.Ruan Q, Yang K, Wang X, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med*. 2020;48(5):846-8. 15.Shu S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol*. 2020. 16.Mahajan K, Chandra S. Cardiovascular comorbidities and complications associated with coronavirus disease 2019: Medical Journal. *Armed Forces India*. 2020. 17.Zhou T, Yu T, Du R, Li Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-62. 18.Ortgin E, Madhavan MV, Bickel B, Chuich T, Laracy J, Biondi-Zoccali G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. *J Am Coll Cardiol*. 2020;75(18):2352-71. 19.Lazzerini PE, Boujdir M, Capocchi PL. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! *Circulation*. 2020. 20.Mahajan K, Chandra S. Cardiovascular comorbidities and complications associated with coronavirus disease 2019. *Medical Journal, Armed Forces India*. 2020. 21.Singhphong B, Nazarian S, Muser D, Deo R, Santarpil P, Chugh MY, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. *Heart Rhythm*. 2020. 22.Guiz TI, Mohiddin SA, Dimarco A, Patel V, Savastis K, Marrelli-Berg PM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc Res*. 2020. 23.Rodriguez DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. *Cardiovasc Res*. 2019;115(5):895-903. 24.Kim IC, Kim HA, Park JS, Nam CW. Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives. *Korean Circ J*. 2020;50(7):543-54. 25.Bangalore S, Sharma A, Slotwimer A, Vatskar L, Harari R, Shah B, et al. ST-Segment Elevation in Patients with Covid-19 - A Case Series. *N Engl J Med*. 2020;382(25):2478-80. 26.Chang D, Saleh M, Garcia-Bengo Y, Choi E, Epstein L, Willner J. COVID-19 Infection Unmasking Brugada Syndrome: Heart Rhythm Case Rep. 2020. 27.Vidovich MI. Transient Brugada-like ECG pattern in a patient with Coronavirus Disease 2019 (COVID-19). *JACC Case Rep*. 2020. 28.Mahadevasani G, Aleem A, Secaira A, Saha S, Shariff M. ST Elevation in a Patient With COVID-19 Infection-Associated Fever: A Case of Brugada Pattern. *Circus*. 2020;12(6):e8722. 29.Asl F, Ali Z. Transient ST Segment Elevation in Two Patients With COVID-19 and a Normal Thoracostic ECG. *Eur J Case Rep Intern Med*. 2020;7(15):001672. 30.Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020;17(5):259-60. 31.Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J (Engl)*. 2020;133(9):1025-31. 32.Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasini D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020. 33.Rehman M, Gondal A, Rehman NU. Atypical Manifestation of COVID-19-Induced Myocarditis. *Cureus*. 2020;12(6):e8685. 34.Fried JA, Ramasubbu K, Bharti R, Topkara VK, Cierkin NJ, Horn E, et al. The Variety of Cardiovascular Presentations of COVID-19. *Circulation*. 2020;141(21):1530-6. 35.Correa-Medina VJ, Alvarez KH, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular. 36.Purtmann VO, Carey ML, Wietes J, Fahim M, Arendt C, Hoffmann A, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*. 2020. 37.Taylor AJ, Salerno, M., Dharmakumar, R., & Jerosch-Herold, M. (2016). T1 Mapping: Basic Techniques and Clinical Applications. *JACC Cardiovascular Imaging*, 9(1), 67-81. doi:10.1016/j.jcmg.2015.11.005